Kornimate/medical-research-clean huggingface dataset:
assessing the impact of isokinetic muscular strengthening in eccentric mode in the medical treatment of knee osteoarthritis

Conditions: Unilateral Knee Osteoarthritis

Summary: knee osteoarthritis (o.a. from now on) is associated to muscular weakness of inferior limbs, especially the quadriceps; leading to disease progression. advantages of muscular strength training for the treatment of this kind of o.a. is now well established. in this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises. functional impairment caused by knee o.a. is mainly affecting walking. walking induces muscles to work in eccentric mode. the hypothesis of this study is that muscular strengthening using isokinetic exercises in eccentric mode would have a more important benefit than isokinetic exercises in concentric mode. such an hypothesis, if verified, could lead to a better management of rehabilitative knee exercises in the treatment of knee o.a.

knee osteoarthritis (o.a. from now on) is associated to muscular weakness of inferior limbs, especially the quadriceps; leading to disease progression. advantages of muscular strength training for the treatment of this kind of o.a. is now well established. in this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises. functional impairment caused by knee o.a. is mainly affecting walking. walking induces muscles to work in eccentric mode. the hypothesis of this study is that muscular strengthening using isokinetic exercises in eccentric mode would have a more important benefit than isokinetic exercises in concentric mode. such an hypothesis, if verified, could lead to a better management of rehabilitative knee exercises in the treatment of knee o.a.

Eligibility criteria:
inclusion criteria: * patient male or female, age ranging from 40 to 70 years old * patient suffering from one-sided knee o.a. regarding criteria of the american college of rheumatology (a.c.r.), with radiologic score ranging from 2 to 3 according to the kellgren \& lawrence classification. * patient receiving medical support * patient that did not receive any infiltration on knee within two months before randomisation. * patient free from any disease that could be a contraindication to the study treatment * patient able to understand the protocol and willing to comply with its rules. * patient willing to give consent. * patient affiliated to the french social secu exclusion criteria: * patient carrying prosthesis. * patient suffering from inflammatory arthritis, or flare of arthritis. * patient suffering from symptomatic patellofemoral osteoarthritis. * patient suffering from cardio-vascular or pneumologic disease that could a contraindication to the study treatment. * patient suffering from any pathology that could cause muscular weakness (myopathy, neuropathy, hemiplegia...)

Keywords: knee osteoarthritis exercise isokinetic muscle strength rehabilitation
effects of resistance and endurance training on synthesis of individual muscle proteins in young and older adults

Conditions: Sarcopenia

Summary: loss of skeletal muscle strength and skeletal muscle mass occurs with of aging. this are-related decline in skeletal muscle mass and skeletal muscle strength is a major underlying factor contributing to many of the metabolic disorders and frailty of the investigators rapidly expanding aging population. endurance (aerobic) and resistance exercise training programs have been shown to effectively reverse the age-related decline in metabolic and contractile muscle functions. the investigators will measure synthesis rates of individual muscle proteins in 36 each of young (18-30 yrs) and 36 older (\> 65 yrs) people to determine their response to 8 weeks each of endurance, resistance, combined endurance and resistance training, or placebo exercise training. hypotheses. 1. to measure fractional synthesis rates of multiple muscle proteins and identify those that are enhanced by an endurance exercise program 2. to determine whether changes in protein synthesis in response to endurance exercise programs are dependent on age 3. to measure fractional muscle synthesis rates of multiple muscle proteins and to identify those that are enhanced by a resistance exercise program 4. to determine whether changes in protein synthesis in response to resistance exercise programs are dependent on age


Eligibility criteria:
inclusion criteria: * healthy * 18 to 30 or \>65 years * males and females exclusion criteria: * regular exercise program * smoking * cardiometabolic disease (diabetes, cardiovascular disease, thyroid disorders) * drugs known to impair metabolic function (beta blockers, steroids) * allergies to lidocaine * physical disability that precludes exercise

Keywords: exercise aging sarcopenia mitochondria
baclofen for the treatment of alcohol drinkers

Conditions: Alcoholism

Summary: the main objective of this study is to show the effectiveness to a year of baclofen compared to placebo, on the proportion of patients with a low risk alcohol consumption or no, according to the who standards.

baclofen, a gamma-aminobutyric acid 'b-receptor' agonist, has long been used to treat spasticity from neurological diseases, at a dose of 30-90 mg/day. it appears today to be a promising but controversial candidate for treating alcoholic patients (enserick, 2011) by reducing or even suppressing their craving to drink. a few case reports (ameisen, 2005; bucknam, 2007; dore et al., 2011) and a retrospective study (rigal et al, 2012) suggest that some patients might respond favorably to baclofen at higher doses than 90 mg/day. this is a randomized controlled trial versus placebo testing such doses. an extraction of patients dna and a genetic analysis will be done after the end of the trial. in a gene candidate approach, the association of several genes with the efficiency of the treatment and its side effects, based on the literature, will be investigated using micro-array technology.

Eligibility criteria:
inclusion criteria: * patient coming for a problem with alcohol (alcohol at high risk during the past three months (at least two times during each month) according to the who standards;. i.e.: in women more than 40 g per day or 280 g per week or more of 40 g at once; the man more than 60 g per day or 420 g per week or more than 60 g in once, and expressing the desire to be abstinent or to have a consumption to low level of risk). * volunteer to participate in the trial and having given his consent written after appropriate information * patient having no treatment for the maintenance of abstinence (acamprosate, naltrexone) and the prevention of relapse (disulfiram) for at least 15 days before the beginning of the trial * patient informed about the possibility of drowsiness in relation to the treatment and the associated risks to drive vehicles (motorized or not), the use of machines (including domestic use or recreation) and the execution of tasks requiring attention and precision * including woman of childbearing age (but taking effective contraception). exclusion criteria: * patient taking already baclofen or having taken baclofen * patient pregnant, lactating, or childbearing years in the absence of effective contraception * patient with porphyria * patient with parkinson's disease * patient with severe psychiatric pathology (psychosis, including schizophrenia and bipolar disorders) that can compromise the observance * patient with organic disease serious enough to not to allow its inclusion in the study according to the opinion of the investigator * patient homeless * patient without social cover * patient unable to properly follow-up book, cannot commit to one year of follow-up * patient with a contraindication to taking baclofen (intolerance to gluten by the presence of wheat starch * patient with a severe intolerance known about the lactose

Keywords: high dose baclofen alcoholism abstinence low risk consumption craving
the effect of core stabilization exercises on balance and quality of life in chronic period in individuals with lumbar disc herniation

Conditions: Lumbar Disc Herniation; Balance; Distorted

Summary: the effect of core stabilization exercises on balance and quality of life in chronic period in individuals with lumbar disc herniation

this study was carried out to examine the effect of core stabilization exercises on balance and quality of life in the chronic period in individuals with lumbar disc herniation. forty patients aged 45-65 years who had been diagnosed with lumbar disc herniation at least one year ago were included in the study. by randomization, they were divided into 2 groups of 20 people, each being the treatment and the control group. a self-prepared form for patient demographic information, mcgill pain scale and visual analog scale(vas) for pain assessment; diasu gait analysis device and berg balance scale for static balance assessment; timed up and go test, y balance diagram, functional reach test to evaluate dynamic balance; tinetti fall efficiency scale for assessing falls; the oswestry disorder scale and nottingham health profile were used to assess quality of life and functionality; to evaluate proprioceptive sensation, ankle joint position sense was measured in standing, neutral position (0˚) and angular measurement in 10˚ dorsiflexion. after the questionnaires and measurement tools were completed, the patients were included in the program. while the patients in the control group continued their routine lives, the modified pilates exercise program focused on core stabilization was applied to the patients in the treatment group for 8 weeks, 2 days a week for 50 minutes and in 4 groups. after the treatment process was completed, the questionnaires and measurements were repeated.

Eligibility criteria:
inclusion criteria: * individuals aged 45 and over with a diagnosis of lumbar disc herniation, * not having any communication barriers (sight, hearing, hearing), * have not undergone any surgical procedure in the last 6 months, * patients who volunteered to participate in the study exclusion criteria: * those who do not want to participate in the study, * individuals whose age is unsuitable, * individuals who continue to receive a therapeutic exercise therapy, * individuals with a neurological condition that may affect ankle muscle strength and sensation

Keywords: lumbar disc herniation, chronic period, balance, core stabilization, proprioceptive sense
belgian cross-sectional allogeneic transplant survivor study

Conditions: Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cell Transplantation, Allogeneic

Summary: with the increasing successful use of allogeneic hematopoietic stem cell transplantation (hsct) to cure advanced hematological disease, it becomes essential to evaluate the long-term effects of such a drastic treatment. this study investigates the prevalence of several demographic, psychosocial and behavioral aspects of survivorship after an allogeneic transplantation. income, return to work, social isolation, pain, medication adherence, influenza vaccination status, alcohol use, smoking habits, drug use, healthy diet, prevention of uv exposure, physical activity, functional status/quality of life (qol), couple life/sexual function, depression, anxiety, spirituality and resilience will be studied.

this is a cross sectional study, where participants are interviewed and fill in a self reported survey. the interview and survey are only taken once. it is non interventional because the patients only give us extra information, which is not usually recorded in our medical records.

Eligibility criteria:
inclusion criteria: * ability to read and write in dutch * age above 18 years at time of transplant * transplanted in uz leuven between 1992 and 2012 with an allogeneic donor (i.e. being at least 2 years post-tx) * presenting for a periodic health check in uzleuven from november 15th, 2014 to november 15th 2016 * willing to provide oral and written consent exclusion criteria: * unable to communicate fluently in dutch * presenting with major visual, hearing, cognitive or psychiatric conditions precluding participation * presenting with relapse or other major illness, with less than 6 months expected survival * hospitalized for a life-threatening condition
fluid resuscitation with hes 200/0.5 10% in severe burn injury

Conditions: Survival; Renal Failure

Summary: hes 200/0.5 10% is equal to ringers lactat solution.

30 patients were enrolled to the study, either to the hyperoncotic hes 200/0.5 (10%) group or to the crystalloids only group. after a treatment protocol of 72 hours we collected data about complications like pulmonary failure and abdominal compartment syndrome. furthermore, we addressed the question of incidence of mortality and renal failure.

Eligibility criteria:
inclusion criteria: * all burn victims with burned surface area bigger than 20% exclusion criteria: * pregnancy
hemodynamic estimation of the result of the mitraclip technique: interest of the ratio of mean arterial pressure (map) to pressure of the mean left atrium (pog) (mitrapog)

Conditions: Mitral Insufficiency; Mitraclip

Summary: this research is based on the hypothesis that the measurement of the ratio of mean arterial pressure to mean left atrium pressure and of its evolution during the procedure, would make it possible to assess the immediate success of the procedure by supplementing the results of the ultrasound. the main objective of this research is to define the percentage of improvement in the mean arterial pressure / mean left atrium pressure ratio at the end of the procedure to validate the success of the mitraclip procedure.


Eligibility criteria:
inclusion criteria: * woman or man over 18 years old * patient with symptomatic mitral leakage (grade 3+ or 4+) at high surgical risk defined as: * age ≥ 75 years and an sts score ≥ 6%, or, according to mvarc, at least 1 fragility index or at least 1 organ fragility criterion or at least 1 operative risk criterion. mvarc recommendations are defined in the appendix. * age \ 8%, or, according to mvarc, at least 1 fragility index or at least 1 organ fragility criterion or at least 1 operative risk criterion. mvarc recommendations are defined in the appendix. * patient rejected for surgery. * patient with a life expectancy of over 1 year. * patient affiliated or beneficiary of a social security scheme. * patient having been informed and having signed a written consent. exclusion criteria: * patient with unfavorable ultrasound parameters (for example: patient with insufficient mitral surface). * patient with recent or active infection. * patient with a contraindication to the transseptal puncture. * patient with valve anatomy incompatible with the placement of the device. * patient with an anomaly of the tricuspid valve justifying a surgical intervention. * patient who has had a percutaneous cardiovascular procedure within the previous 30 days. * patient who had heart surgery in the previous 30 days. * patient with a history of surgery on the mitral valve. * patient having had a stroke in the previous 30 days. * patient participating in another clinical study. * protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision. * pregnant, breastfeeding or parturient woman. * patient hospitalized without consent.
effect of henagliflozin on cardiac function in type 2 diabetes patients with chronic heart failure (hero-hf)

Conditions: Heart Failure

Summary: the purpose of this study is to determine the superiority of the effectiveness of henagliflozin 10 milligram (mg) daily versus blank control in participants with type ii diabetes (t2dm) and symptomatic heart failure (hf) in improving the overall kansas city cardiomyopathy questionnaire (kccq) clinical summary score (css).


Eligibility criteria:
inclusion criteria: * patients with t2dm aged ≥18 years * 6.5%≤hba1c≤11% * clinically stable symptomatic heart failure (a) for hfref: (a) ejection fraction (ef) less than or equal to (\ ) 40%; (b) diagnosis of chronic heart failure within the past 18 months * symptoms of heart failure at visit 1 (nyha ii-iv) * kccq-oss score \< 80 at screening visit * nt-probnp \> 125 pg/ml, or nt probnp \> 365 pg/ml in atrial fibrillation patients; or bnp \> 35 pg/ml, or bnp \> 105 pg/ml in atrial fibrillation patients at screening visit * subject must have received (and be receiving) at least one stable optimal dose of guidelines recommended hf drugs (e.g., acei, arb, arni, beta blockers, oral diuretics, mra) prior to visit 1 * egfr≥30 ml/min/1.73m2 at screening visit (ckd-epi formula) * signed and dated written icf exclusion criteria: * pregnant and lactating women and women of childbearing age who do not want to use reliable contraception * known allergy to henagliflozin * hospitalization for acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 4 weeks before the screening visit * acute decompensated heart failure or hospitalization for decompensated heart failure within 4 weeks * history of heart transplantation or ventricular assist device (vad), or intention to heart transplantation or vad * perinatal or chemotherapy-induced cardiomyopathy within 12 months * documented untreated ventricular arrhythmias with syncope within 3 months * diagnosed respiratory diseases * type i diabetes * t2dm with history of ketoacidosis (dka) * uncontrolled hypertension, defined as systolic blood pressure ≥160 mmhg and/or diastolic blood pressure ≥100 mmhg at screening visit * symptomatic hypotension and/or systolic blood pressure \<90 mmhg at visit 0 or visit 1, or hypovolemia * history of recurrent urinary and reproductive tract infections * current use or prior use of a sglt-2i or glp-1ra within 3 months * diagnosed malignant tumors * further exclusion criteria apply

Keywords: heart failure henagliflozin
study to evaluate the efficacy and safety of combined administration of tak-536ccb and hydrochlorothiazide in patients with grade i or ii essential hypertension.

Conditions: Grade I or II Essential Hypertension

Summary: the objective of this study is to compare the efficacy and safety of combined administration of tak-536ccb (fix-dose combination of azilsartan and amlodipine) and hydrochlorothiazide (hctz) with those of tak-536ccb in patients with grade i or ii essential hypertension.

this study is a randomized, double-blind, multicenter, phase 2/3 study to evaluate the efficacy and safety of combined administration of tak-536ccb and hydrochlorothiazide (hctz) with those of tak-536ccb or hydrochlorothiazide in patients with grade i or ii essential hypertension. this study consists of a 4-week single-blind placebo run-in period and a 10-week double-blind treatment period.

Eligibility criteria:
inclusion criteria: 1. grade i or ii essential hypertension. 2. an office sitting systolic blood pressure of ≥ 150 and \< 180 mmhg, and an office sitting diastolic blood pressure of ≥ 95 and \< 110 mmhg during the placebo run-in period at week -2 and week 0. 3. male or female aged 20 years or older at the time of providing informed consent. 4. outpatient. exclusion criteria: 1. secondary hypertension, grade iii hypertension or malignant hypertension. 2. an office sitting systolic blood pressure of ≥160 mmhg or sitting diastolic blood pressure of ≥100 mmhg recorded while on combined therapy with 3 or more antihypertensives within 4 weeks prior to the initiation of the placebo run-in period and at week -4. 3 evident white coat hypertension or white coat phenomenon. 4. day-night reversed lifestyle, such as night-time workers. 5. sleep apnea syndrome requiring treatment. 6. have any of the cardiovascular disease or symptoms listed below: * heart disease: myocardial infarction (within 24 weeks before the placebo run-in period), coronary arterial revascularization (within 24 weeks before the placebo run-in period), severe valvular disease, atrial fibrillation, or following diseases which require medication: angina pectoris, congested heart failure, or arrhythmia. * cerebrovascular disease: cerebral infarction, cerebral hemorrhage (within 24 weeks before the placebo run-in period), or transient ischemic attack (within 24 weeks before the placebo run-in period). * vascular diseases: peripheral arterial disease with intermittent claudication, artery dissection, aneurysm * advanced hypertensive retinopathy: bleeding, exudation, or papilledema (within 24 weeks before the placebo run-in period). 7. clinically significant hepatic disorder. 8. clinically significant renal impairment. 9. significantly low or high potassium or sodium levels. 10. complicated by gout, or had a past history of gout within 24 weeks prior to the initiation of the placebo run-in period, or complicated by hyperuricemia requiring medication. 11. diabetic subject on insulin treatment or poorly controlled type 2 diabetes mellitus. 12. have a malignant tumor.

Keywords: hypertension, drug therapy
buccal mucosal graft for the repair of iatrogenic pelviureteric junction obstruction or ureteric stricture.

Conditions: Pelvi Ureteric Junction Obstruction or Ureteral Stricture

Summary: prospective study to evaluate the safety and efficacy of using buccal mucosal graft for repairing complex cases of iatrogenic pelvi ureteric junction obstruction and long segment ureteric stricture disease.

a graft of buccal mucosa will be used to augment either the narrow unhealthy pelviureteric junction or a narrow long segment of the ureter. after freeing the narrowed part, a posterior incision will be made in the ureter or renal pelvis then the graft will be implanted on the psoas muscle using interrupted sutures in a position the allows easy anastomosis to the ureter or renal pelvis. alternatively a lateral incision in the renal pelvis or the ureter may be done for the graft anastomosis and then surrounded with omenal flap to ensure a good blood supply for the graft.

Eligibility criteria:
inclusion criteria: - any patient with iatrogenic pelviureteric junction obstruction or long segment ureteric stricture exclusion criteria: * elderly patients unfit for general anaesthesia.
research on the application of ai image recognition-based smartphone apps in personalized bowel preparation

Conditions: Colorectal Polyps

Summary: colorectal cancer, as one of the most common malignant tumors of the digestive system, has a high incidence and mortality rate worldwide. high-quality colonoscopy is essential for the early detection and prevention of colorectal cancer and is key to improving the survival rates of patients. however, traditional colonoscopy faces numerous challenges in bowel preparation, such as inadequate preparation and a lack of personalized cleansing approaches. therefore, it is particularly important to develop timely and efficient individualized bowel preparation methods. artificial intelligence, especially deep learning technologies, has shown great potential in the medical field. this study aims to leverage the advantages of artificial intelligence to optimize the bowel preparation process before colonoscopy, creating a personalized bowel preparation plan that effectively improves the efficacy of colorectal cancer screening and diagnosis.


Eligibility criteria:
inclusion criteria: * patients who underwent painless colonoscopy at the digestive endoscopy center of the first affiliated hospital of zhengzhou university and signed the informed consent for the clinical trial. individuals who use smartphones. exclusion criteria: * patients with contraindications for colonoscopy. individuals in whom successful cecal intubation could not be achieved.

Keywords: colonoscopy bowel preparation artificial intelligence smartphone bbps score